12/10/2024
6:03 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/02/2024
6:03 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/14/2024
11:22 AM | CVI Investments, Inc. (Filed by)
RedHill Biopharma (Subject)
| Form SC 13G/A | |
10/28/2024
6:01 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/22/2024
6:01 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/15/2024
5:02 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/01/2024
6:02 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/30/2024
6:01 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/18/2024
8:00 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/17/2024
8:13 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/09/2024
6:04 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
|
09/05/2024
7:30 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/05/2024
6:05 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/03/2024
6:03 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/29/2024
6:07 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/26/2024
6:02 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/21/2024
6:04 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/19/2024
11:15 PM | RedHill Biopharma (Filer)
| Form EFFECT | |
08/19/2024
6:01 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/16/2024
6:13 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/13/2024
12:37 PM | RedHill Biopharma (Filer)
| Form 424B3 | |
08/13/2024
7:35 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/09/2024
6:01 AM | RedHill Biopharma (Filer)
| Form F-3
Registration statement for securities of certain foreign private issuers | |
08/07/2024
3:43 PM | Quintairos, Prieto, Wood & Boyer P.A. (Filed by)
RedHill Biopharma (Subject)
| Form SCHEDULE 13D | |
08/07/2024
8:51 AM | RedHill Biopharma (Filer)
| Form 424B3 | |
08/06/2024
6:00 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/01/2024
6:05 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/22/2024
6:04 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/09/2024
7:03 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/20/2024
6:23 AM | RedHill Biopharma (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
06/06/2024
8:00 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/03/2024
6:04 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/06/2024
6:01 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/24/2024
6:05 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/22/2024
11:15 PM | RedHill Biopharma (Filer)
| Form EFFECT | |
04/18/2024
6:00 AM | RedHill Biopharma (Filer)
| Form POS AM | |
04/08/2024
8:25 AM | RedHill Biopharma (Filer)
| Form 20-F
Registration statement / Annual report / Transition report | |
04/08/2024
8:28 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/04/2024
3:05 PM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/03/2024
6:00 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/02/2024
6:02 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad) Elon Musk believes his new AI product will be worth an incredible $9 trillion.
But the mainstream media is not buying it. Click here to watch this demo and decide for yourself. |
03/20/2024
3:38 PM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/11/2024
6:01 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/05/2024
6:01 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/20/2024
6:01 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/16/2024
7:54 AM | RedHill Biopharma (Filer)
| Form 424B3 | |
02/15/2024
11:15 PM | RedHill Biopharma (Filer)
| Form EFFECT | |
02/09/2024
3:20 PM | RedHill Biopharma (Filer)
| Form F-1
Registration statement for securities of certain foreign private issuers | |
02/05/2024
7:00 AM | RedHill Biopharma (Filer)
| Form D
Notice of Exempt Offering of Securities | |
02/01/2024
9:22 AM | CVI Investments, Inc. (Filed by)
RedHill Biopharma (Subject)
| Form SC 13G | |
01/26/2024
11:50 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/26/2024
8:29 AM | RedHill Biopharma (Filer)
| Form 424B5 | |
01/26/2024
8:31 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/25/2024
8:09 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/25/2024
5:02 AM | RedHill Biopharma (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
